Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Siemens Healthineers stock jumps on solid fiscal year results

Published 06/11/2024, 16:06
Updated 06/11/2024, 16:08
© Reuters.
SHLG
-

Shares in Siemens (ETR:SIEGn) Healthineers popped more than 7% Wednesday after the company achieved its full-year targets for revenue and profit growth, as strong performances from its Imaging division and the U.S.-based cancer treatment unit, Varian, in the fourth quarter compensated for softer results in China.

The German medtech giant reported comparable annual revenue growth of 4.7% for the fiscal year ending Sept. 30, just below analysts' consensus forecast of 4.8% as compiled by Vara Research, and hitting the low end of Siemens Healthineers' projected 4.5%-6.5% range.

Adjusted EBIT reached 3.5 billion euros ($3.77 billion), aligning with analysts' expectations.

In China, revenue fell by a mid-single-digit percentage in the fourth quarter due to delayed customer orders, although Siemens Healthineers noted "very strong" comparable revenue growth in the Americas.

"We assume China revenue in the first half of fiscal year 2025 to decline mid-single-digit to high-single-digit percentage points," said the company’s CFO Jochen Schmitz.

"In the second half of 2025, we assume revenue to be roughly at the level of the second half of fiscal 2024,” he added.

CEO Bernd Montag emphasized that, despite current challenges, China remains a valuable market for the medium and long term.

Looking ahead, Siemens Healthineers forecasts comparable revenue growth of 5%-6% in 2025 and anticipates adjusted basic earnings per share between 2.35 euros and 2.50 euros.

While the earnings guidance sits slightly below the consensus estimate of €2.53, investors “may welcome an initially cautious guide, leaving room for upgrades if/when China normalizes,” Jefferies analysts commented.

“With shares broadly flat YTD, we believe the valuation is appealing,” they noted.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.